Moderna Inc. recently announced it is advancing three Phase I clinical trials of Human immunodeficiency virus (HIV) vaccines with partners (mRNA-1644/IAVI G002; mRNA-1644/IAVI G003; mRNA-1574/NIAID) to expand on proof-of-concept data.
And these trials will evaluate the potential of Moderna's mRNA technology to successfully deliver immunogens and will be conducted in parallel to accelerate the advancement of immunogens into vaccine candidates.
mRNA Vaccines Targets HIV
Post-COVID-19 Condition Tied to Health Care Access Issues
Adults reporting post-COVID-19 condition say they have trouble getting, paying for care